{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:08:08Z","timestamp":1792267688497,"version":"4.4.0"},"reference-count":126,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation, growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause downstream activation of kinases, leading to uncontrolled cellular growth and carcinogenesis. Therefore, inhibition of BRAF and the downstream substrate MEK has been shown to be effective in controlling tumor growth and proliferation. Over the last decade, several BRAF and MEK inhibitors have been investigated, ranging from primarily melanoma to various cancer types with BRAF alterations. This subsequently led to several Food and Drug Administration (FDA) approvals for BRAF\/MEK inhibitors for melanoma, non-small cell lung cancer, anaplastic thyroid cancer, colorectal cancer, histiocytosis neoplasms, and finally, tumor-agnostic indications. Here, this comprehensive review will cover the developments of BRAF and MEK inhibitors from melanomas to tumor-agnostic indications, novel drugs, challenges, future directions, and the importance of those drugs in personalized medicine.<\/jats:p>","DOI":"10.3390\/ijms25010624","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:31:50Z","timestamp":1704281510000},"page":"624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Molecular Targeting of the BRAF Proto-Oncogene\/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-0024","authenticated-orcid":false,"given":"Khine S.","family":"Shan","sequence":"first","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tauseef U.","family":"Rehman","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelenis","family":"Domingo","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2669-5771","authenticated-orcid":false,"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[{"name":"Memorial Health Care, Thoracic Oncology Program, Pembroke Pines, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Schubert, L., Mariko, M.L., Clerc, J., Huillard, O., and Groussin, L. (2023). MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. Cancers, 15.","DOI":"10.3390\/cancers15030710"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sforza, V., Palumbo, G., Cascetta, P., Carillio, G., Manzo, A., Montanino, A., Sandomenico, C., Costanzo, R., Esposito, G., and Laudato, F. (2022). BRAF Inhibitors in Non-Small Cell Lung Cancer. Cancers, 14.","DOI":"10.3390\/cancers14194863"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dillon, M., Lopez, A., Lin, E., Sales, D., Perets, R., and Jain, P. (2021). Progress on Ras\/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 13.","DOI":"10.3390\/cancers13205059"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"772052","DOI":"10.3389\/fonc.2021.772052","article-title":"BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?","volume":"11","author":"Aldegheri","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: From melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","article-title":"AACR Project GENIE: 100,000 Cases and Beyond","volume":"12","author":"Pugh","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Szklener, K., Mazurek, M., Wieteska, M., Wac\u0142awska, M., Bilski, M., and Ma\u0144dziuk, S. (2022). New Directions in the Therapy of Glioblastoma. Cancers, 14.","DOI":"10.3390\/cancers14215377"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Savoia, P., Fava, P., Casoni, F., and Cremona, O. (2019). Targeting the ERK Signaling Pathway in Melanoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061483"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_10","unstructured":"Drugs.com (2023, November 09). FDA Approves Zelboraf and Companion Diagnostic Test for Late-Stage Skin Cancer. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-zelboraf-companion-diagnostic-test-late-stage-skin-cancer-2814.html."},{"key":"ref_11","unstructured":"Drugs.com (2023, November 09). FDA Approves Tafinlar (Dabrafenib) for Advanced Melanoma. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-tafinlar-dabrafenib-advanced-melanoma-3797.html."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/jco.2013.31.15_suppl.9013","article-title":"An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)","volume":"31","author":"Hauschild","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","unstructured":"Drugs.com (2023, November 09). FDA Approves Mekinist (Trametinib) for Advanced Melanoma. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-mekinist-trametinib-advanced-melanoma-3798.html."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","article-title":"Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K\u2013mutant advanced or metastatic melanoma","volume":"109","author":"Robert","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","unstructured":"Drugs.com (2023, November 09). GSK Gains Accelerated FDA Approval for Combination Use of Mekinist (Trametinib) and Tafinlar (Dabrafenib). Available online: https:\/\/www.drugs.com\/newdrugs\/gsk-gains-accelerated-fda-approval-combination-mekinist-trametinib-tafinlar-dabrafenib-4003.html."},{"key":"ref_22","unstructured":"Drugs.com (2023, November 09). FDA Approves Cotellic (Cobimetinib) for the Combination Treatment of Advanced Melanoma. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-cotellic-cobimetinib-combination-advanced-melanoma-4295.html."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","unstructured":"Drugs.com (2023, November 09). Novartis Receives FDA Approval of Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanoma. Available online: https:\/\/www.drugs.com\/newdrugs\/novartis-receives-fda-approval-tafinlar-mekinist-adjuvant-braf-v600-mutant-melanoma-4733.html."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation\u2013Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_32","unstructured":"Drugs.com (2023, November 09). Array BioPharma Announces FDA Approval of Braftovi (Encorafenib) in Combination with Mektovi (Binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations. Available online: https:\/\/www.drugs.com\/newdrugs\/array-biopharma-announces-fda-approval-braftovi-encorafenib-combination-mektovi-binimetinib-4771.html."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients with BRAF V600\u2013Mutant Melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients with Tumors with BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E\u2013Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer","volume":"41","author":"Taieb","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/2159-8290.CD-19-1265","article-title":"Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study","volume":"36","author":"Kaley","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00266","article-title":"Efficacy of Vemurafenib in Patients with Non\u2013Small-Cell Lung Cancer with BRAFV600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study","volume":"3","author":"Subbiah","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600\u2013Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation\u2013positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","article-title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","volume":"31","author":"Mazieres","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAFV600-Mutant Metastatic Non\u2013Small-Cell Lung Cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","article-title":"Dabrafenib, alone or in combination with trametinib, in BRAF V600\u2013mutated pediatric Langerhans cell histiocytosis","volume":"7","author":"Whitlock","year":"2023","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): An international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1200\/JCO.2022.40.16_suppl.9516","article-title":"Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E\/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3","volume":"40","author":"Ribas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"175883592199297","DOI":"10.1177\/1758835921992974","article-title":"BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer","volume":"13","author":"Ros","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_57","unstructured":"Drugs.com (2023, November 09). FDA Approves Braftovi (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) after Prior Therapy. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-braftovi-encorafenib-combination-cetuximab-brafv600e-mutant-metastatic-colorectal-5201.html."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients with BRAF V600E\u2013Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study","volume":"37","author":"Huijberts","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"TPS3619","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3619","article-title":"BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) \u00b1 chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100378","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-016-0432-2","article-title":"Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice","volume":"17","author":"Jain","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_63","unstructured":"Drugs.com (2023, November 09). Novartis Tafinlar + Mekinist Receives FDA Approval for First Tumor-Agnostic Indication for BRAF V600E Solid Tumors. Available online: https:\/\/www.drugs.com\/newdrugs\/novartis-tafinlar-mekinist-receives-fda-approval-first-tumor-agnostic-indication-braf-v600e-solid-5857.html."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2020.05.021","article-title":"Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations","volume":"15","author":"Negrao","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Guaitoli, G., Zullo, L., Tiseo, M., Dankner, M., Rose, A.A., and Facchinetti, F. (2023). Non-small-cell lung cancer: How to manage BRAF-mutated disease. Drugs Context, 12.","DOI":"10.7573\/dic.2022-11-3"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtho.2018.04.024","article-title":"BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors","volume":"13","author":"Dudnik","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1200\/JCO.2017.35.15_suppl.9072","article-title":"BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies","volume":"35","author":"Reddy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/1078-0432.CCR-14-2124","article-title":"MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking","volume":"21","author":"Arcila","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_69","unstructured":"FDA.gov (2023, September 09). FDA Grants Regular Approval to Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-dabrafenib-and-trametinib-combination-metastatic-nsclc-braf-v600e."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Garutti, M., Bergnach, M., Polesel, J., Palmero, L., Pizzichetta, M.A., and Puglisi, F. (2022). BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15010141"},{"key":"ref_71","unstructured":"Drugs.com (2023, November 18). FDA Approves Braftovi (Encorafenib) with Mektovi (Binimetinib) for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-braftovi-encorafenib-mektovi-binimetinib-metastatic-non-small-cell-lung-cancer-braf-6111.html."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF Mutations in Hairy-Cell Leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2011-08-371179","article-title":"Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/10428194.2016.1185786","article-title":"Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant","volume":"58","author":"Mason","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/bloodadvances.2022009013","article-title":"Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: A multicenter analysis","volume":"7","author":"Aaroe","year":"2023","journal-title":"Blood Adv."},{"key":"ref_79","unstructured":"Drugs.com (2023, November 18). FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-zelboraf-vemurafenib-erdheim-chester-braf-v600-mutation-4625.html."},{"key":"ref_80","unstructured":"Drugs.com (2023, November 18). FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms, Research Led by Memorial Sloan Kettering Cancer Center. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-oral-mek-inhibitor-cobimetinib-histiocytic-neoplasms-research-led-memorial-sloan-5984.html."},{"key":"ref_81","first-page":"1067252","article-title":"Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution","volume":"12","author":"Gatto","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_84","first-page":"e220062","article-title":"Kinase inhibitors in thyroid cancers","volume":"3","author":"Sukrithan","year":"2023","journal-title":"Endocr. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S1204","DOI":"10.1016\/j.annonc.2021.08.889","article-title":"1743MO MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation","volume":"32","author":"Leboulleux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_86","first-page":"1124","article-title":"MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer","volume":"33","author":"Leboulleux","year":"2023","journal-title":"Thyroid"},{"key":"ref_87","unstructured":"Drugs.com (2023, November 18). FDA Approves Tafinlar + Mekinist for the Treatment of BRAF-Positive Anaplastic Thyroid Cancer. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-tafinlar-mekinist-braf-positive-anaplastic-thyroid-cancer-4737.html."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib Treatment in Patients with Locally Advanced or Metastatic BRAF V600\u2013Mutant Anaplastic Thyroid Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1158\/1078-0432.CCR-23-0621","article-title":"Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO\/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer","volume":"29","author":"Grisham","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-21-0191","article-title":"New therapeutic opportunities for women with low-grade serous ovarian cancer","volume":"29","author":"Moujaber","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib Versus Physician\u2019s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1470-2045(22)00452-1","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): A multicentre, open-label, single-arm, phase 2 study","volume":"23","author":"Dummer","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_93","unstructured":"Drugs.com (2023, November 18). FDA Approves Genentech\u2019s Tecentriq plus Cotellic and Zelboraf for People with Advanced Melanoma. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-genentech-s-tecentriq-plus-cotellic-zelboraf-advanced-melanoma-5311.html."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600\u2013Mutant Unresectable or Metastatic Melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2217\/fon-2021-1486","article-title":"STARBOARD: Encorafenib + binimetinib + pembrolizumab for first-line metastatic\/unresectable BRAF V600-mutant melanoma","volume":"18","author":"Schadendorf","year":"2022","journal-title":"Future Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Tangella, L.P., Clark, M.E., and Gray, E.S. (2021). Resistance mechanisms to targeted therapy in BRAF-mutant melanoma\u2014A mini review. Biochim. Biophys. Acta (BBA)\u2014Gen. Subj., 1865.","DOI":"10.1016\/j.bbagen.2020.129736"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/1078-0432.CCR-10-2225","article-title":"MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720","volume":"17","author":"Jiang","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J.A., and Comin-Anduix, B. (2011). Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT\/mTOR pathway. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028973"},{"key":"ref_102","first-page":"3585","article-title":"Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells","volume":"36","author":"Luo","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/0008-5472.CAN-14-1174","article-title":"Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy","volume":"74","author":"Kemper","year":"2014","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Krijgsman","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s42764-023-00105-5","article-title":"The mechanism and consequences of BRAF inhibitor resistance in melanoma","volume":"4","author":"Golub","year":"2023","journal-title":"Genome Instab. Dis."},{"key":"ref_108","unstructured":"(2023, November 18). Available online: Clinicaltrials.gov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"TPS10062","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10062","article-title":"FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors","volume":"40","author":"Landi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"TPS3152","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3152","article-title":"Trial in progress: Phase 1a\/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with\/without binimetinib in patients with BRAF V600-mutant solid tumors","volume":"39","author":"Subbiah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"TPS9148","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9148","article-title":"A phase 1\/2 study of VS-6766 (RAF\/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non\u2013small cell lung cancer (NSCLC) (RAMP 203)","volume":"40","author":"Govindan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"TPS5615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5615","article-title":"ENGOT-ov60\/GOG-3052\/RAMP 201: A phase 2 study of VS-6766 (RAF\/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"40","author":"Banerjee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2217\/fon-2021-1582","article-title":"Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: The RAMP-202 phase II trial","volume":"18","author":"Capelletto","year":"2022","journal-title":"Future Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"TPS219","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS219","article-title":"A phase 1b\/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC)","volume":"40","author":"Shergill","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_115","unstructured":"Kilburn, L.B., Khuong-Quang, D.-A., Hansford, J.R., Landi, D., van der Lugt, J., Leary, S.E.S., Driever, P.H., Bailey, S., Perreault, S., and McCowage, G. (Nat. Med., 2023). The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial, Nat. Med., online ahead of print."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"TPS10067","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS10067","article-title":"LOGGIC\/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration","volume":"41","author":"Tilburg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_117","first-page":"15","article-title":"Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma","volume":"92","author":"Rasco","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1158\/1538-7445.AM2021-1473","article-title":"Abstract 1473: Nonclinical development of PF-07284890 (ARRY-461), a potent, brain-penetrant, small molecule inhibitor of BRAF V600-mutation-driven tumors in vitro and in vivo","volume":"81","author":"Bouhana","year":"2021","journal-title":"Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1200\/JCO.2023.41.16_suppl.3098","article-title":"A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors","volume":"41","author":"Nagpal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"CT031","DOI":"10.1158\/1538-7445.AM2023-CT031","article-title":"Abstract CT031: A first-in-human, phase 1a\/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors","volume":"83","author":"Schram","year":"2023","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2023.41.16_suppl.3006","article-title":"Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1\/2a study","volume":"41","author":"Fuente","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-22-0306","article-title":"Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma","volume":"22","author":"Takano","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.2018.36.15_suppl.2583","article-title":"Phase 1\/2 precision medicine study of the next-generation BRAF inhibitor PLX8394","volume":"36","author":"Janku","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1158\/1538-7445.AM2023-3415","article-title":"Abstract 3415: Preclinical characterization of a brain penetrant RAF inhibitor, BDTX-4933, targeting oncogenic BRAF Class I\/II\/III and RAS mutations","volume":"83","author":"Han","year":"2023","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-018-0668-8","article-title":"E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases","volume":"37","author":"Babiker","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-018-0099-5","article-title":"Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: Results of a phase 1 study","volume":"118","author":"Tibes","year":"2018","journal-title":"Br. J. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:39:07Z","timestamp":1760103547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010624"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010624","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]}}}